Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2025.02.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Yukitake Yoshioka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan. Hauptthemen laut MEDLINE: Cholesterol, Oligonucleotides, Antisense, Blood Proteins, Oligonucleotides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Heteroduplex oligonucleotide (HDO) is a novel oligonucleotide therapeutic consisting of an antisense oligonucleotide (ASO) and its complementary RNA. A recent report showed that cholesterol-conjugated HDO (Chol-HDO) exhibited antisense activity in various tissues, including the brain; however, little information is available on the pharmacokinetic and plasma protein-binding properties of HDO and Chol-HDO. In the present study, we investigated the tissue distributions of an ASO, HDO, and Chol-HDO in mice and rats after intravenous injection. Tissue distribution was evaluated by measuring the concentration of ASO in tissue samples using liquid chromatography and tandem mass spectroscopy. ASO and HDO disappeared rapidly from the plasma, whereas Chol-HDO showed prolonged retention in the systemic circulation. The amount of ASO in the brain tissue was highest after injection of Chol-HDO, confirming its efficient delivery to the brain. The tissue distribution of oligonucleotides differed less in rats than in mice. Hepatic uptake of ASO and HDO, but not of Chol-HDO, was significantly inhibited by co-administration with the scavenger receptor inhibitor dextran sulfate sodium. The binding to plasma proteins was evaluated. Compared to ASO, HDO showed lower protein binding, but Chol-HDO showed much higher binding, with remarkable differences in binding to high-density and low-density lipoproteins. The binding of Chol-HDO to these proteins was also confirmed in mouse plasma after injection. These results indicate that the binding of Chol-HDO to plasma proteins, especially lipoproteins, is critical for determining tissue distribution and brain delivery after intravenous injection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
- Center of Excellence for Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
- Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan; Center for Brain Integration Research, Institute of Science Tokyo, Tokyo, Japan…
- Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
- Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan. Electronic address: makiya@rs.tus.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yoshioka, Y., Yamamoto, S., Kusamori, K., Nakayama, M., Fujita, H., Goto, A., Iwasaki, S., Nagata, T., Itakura, S., Kusuhara, H., Yokota, T., Hirabayashi, H., & Nishikawa, M. (2025). Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.02.025
Vancouver
Yoshioka Y, Yamamoto S, Kusamori K, Nakayama M, Fujita H, Goto A, et al. Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.02.025
BibTeX
@article{Yoshioka2025,
author = {Yoshioka, Yukitake and Yamamoto, Syunsuke and Kusamori, Kosuke and Nakayama, Miyu and Fujita, Hisashi and Goto, Akihiko and Iwasaki, Shinji and Nagata, Tetsuya and Itakura, Shoko and Kusuhara, Hiroyuki and Yokota, Takanori and Hirabayashi, Hideki and Nishikawa, Makiya},
title = {Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.02.025}
}
EUVIMED